Ontology highlight
ABSTRACT: Importance
Outcome data are limited regarding early experience with brolucizumab, the most recently approved anti-vascular endothelial growth factor (VEGF) agent for the treatment of neovascular age-related macular degeneration (nAMD).Objective
To report clinical outcomes after intravitreous injection (IVI) of brolucizumab, 6 mg, for nAMD.Design, setting, and participants
This retrospective case series conducted at 15 private or academic ophthalmological centers in the United States included all consecutive patients with eyes treated with brolucizumab by 6 retina specialists between October 17, 2019, and April 1, 2020.Exposures
Treatment with brolucizumab IVI, 6 mg.Main outcomes and measures
Change in mean visual acuity (VA) and optical coherence tom
SUBMITTER: Enriquez AB
PROVIDER: S-EPMC7907988 | biostudies-literature | 2021 Apr
REPOSITORIES: biostudies-literature